Get the Stockscreener App
11.07
3.07%
0.33
Arcus Biosciences Inc stock is traded at $11.07, with a volume of 1.21M.
It is up +3.07% in the last 24 hours and down -21.71% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$10.74
Open:
$11.5
24h Volume:
1.21M
Relative Volume:
1.62
Market Cap:
$1.16B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-3.5825
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-15.50%
1M Performance:
-21.71%
6M Performance:
-37.32%
1Y Performance:
-32.54%
1-Day Range:
$10.81
$11.66
1-Week Range:
$10.63
$12.97
52-Week Range:
$10.63
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
11.07 | 1.16B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Consensus Target Price from Analysts - Defense World
Arcus Biosciences appoints new Chief Medical Officer - MSN
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock - Investing.com
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock By Investing.com - Investing.com Australia
Arcus Biosciences stock hits 52-week low at $10.65 By Investing.com - Investing.com Nigeria
Arcus Biosciences stock hits 52-week low at $10.65 - Investing.com India
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts - Yahoo Finance
Arcus Biosciences stock dips after pricing $150M offering - MSN
Latham & Watkins Advises Arcus Biosciences in US$150 Million Offering of Common Stock - Legal Desire News Network
Arcus Biosciences stock target cut to $18 at H.C. Wainwright By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week low at $13.48 - MSN
Arcus Biosciences stock target cut to $18 at H.C. Wainwright - Investing.com
(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry By Investing.com - Investing.com Nigeria
Arcus Biosciences sets $11/share for $150M stock offering By Investing.com - Investing.com Nigeria
Arcus Biosciences (NYSE:RCUS) Price Target Lowered to $25.00 at Morgan Stanley - Defense World
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst Downgrade - Defense World
Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out - News & Insights
Arcus Biosciences Shares Are Down Today: What's Going On? - Benzinga
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Nigeria
Arcus stock falls as Gilead opts out cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences: Hold Rating Amid Uncertain Future for Casdatifan and Competitive Challenges - TipRanks
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan - Yahoo Finance
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg - Fierce Biotech
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com UK
Arcus Biosciences reports strong cash position, retains casdatifan rights - Investing.com
Gilead looks on as Arcus casdatifan data hints at potential - The Pharma Letter
Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market - Nasdaq
Arcus Biosciences Prices $150 Million Share Offering -February 18, 2025 at 07:34 am EST - Marketscreener.com
Arcus Biosciences reports strong cash position, retains casdatifan rights By Investing.com - Investing.com Canada
Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry - Investing.com
Arcus Biosciences sets $11/share for $150M stock offering - Investing.com India
Arcus Biosciences (RCUS) Expected to Announce Earnings on Wednesday - Defense World
Arcus Biosciences (RCUS) Retains Rights to Casdatifan, and Announces Pricing of $150 Million Common Stock Offering - StreetInsider.com
Major Cancer Drug Development: Arcus Takes Full Control of Breakthrough $5B Treatment After Gilead Exit - StockTitan
Arcus Biosciences (RCUS) Announces 13.64M Share Offering at $11/sh - StreetInsider.com
Arcus Bio Raises Massive $150M War Chest: Major Funding Boost for Cancer Drug Development - StockTitan
Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Down 22.7% in January - MarketBeat
Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Clinical Trial Success: New Kidney Cancer Drug Keeps 87% of Late-Stage Patients Disease-Free - StockTitan
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Lelezard
Arcus Biosciences (NYSE:RCUS) Sets New 1-Year LowShould You Sell? - MarketBeat
Arcus Biosciences’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Arcus Biosciences stock hits 52-week low at $12.13 - MSN
Arcus Biosciences stock hits 52-week low at $12.13 By Investing.com - Investing.com Nigeria
Arcus Appoints CMO With $4.7M Strategic Equity PackageMajor Leadership Move - StockTitan
Revolutionary Renal Cancer Drug Data: Arcus (RCUS) Unveils Clinical Results That Could Reshape Treatment Landscape - StockTitan
Is Arcus Biosciences (NYSE:RCUS) A Risky Investment? - Simply Wall St
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):